Activated aggregation‐induced emission therapeutics agents for triggering regulated cell death

The induction of regulated cell death (RCD) through photo/ultrasound sensitization therapeutic agents has gained significant attention as a vital approach to combat drug resistance in tumors. Aggregation‐induced emission (AIE) therapeutic agents generate reactive oxygen species through photo/ultraso...

Full description

Saved in:
Bibliographic Details
Published in:Aggregate (Hoboken) 2024-06, Vol.5 (3), p.n/a
Main Authors: Zhao, Yu‐Qiang, Yu, Le, Zhang, Lanyun, Liu, Huan, Zhou, Ying, Kim, Jong Seung
Format: Article
Language:English
Subjects:
aggregation‐induced emission
phototherapy
regulated cell death
sonodynamic therapy
therapeutic agents
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The induction of regulated cell death (RCD) through photo/ultrasound sensitization therapeutic agents has gained significant attention as a vital approach to combat drug resistance in tumors. Aggregation‐induced emission (AIE) therapeutic agents generate reactive oxygen species through photo/ultrasound activation, which can synergize with RCD inducers or directly induce RCD, ultimately resulting in the death of tumor cells. The presented comprehensive review delves into recent advancements in AIE therapeutic agents designed to trigger RCD or synergize with RCD inducers, encompassing apoptosis, necroptosis, pyroptosis, immunogenic cell death, autophagy, ferroptosis, and cuproptosis. Additionally, the intricate regulatory mechanisms through which activatory‐AIE therapeutics influence distinct RCD pathways are examined. A forward‐looking perspective on future developments and pertinent challenges within this exciting realm is presented, anticipating the continued evolution of activatable AIE therapeutics as a transformative approach to enhance tumor therapy. This review explores recent advancements in aggregation‐induced emission (AIE) therapeutic agents, addressing apoptosis, necroptosis, pyroptosis, immunogenic cell death, autophagy, ferroptosis, and cuproptosis. Additionally, the review examines the intricate regulatory mechanisms through which activatory‐AIE therapeutics influence distinct regulated cell death pathways. A forward‐looking perspective discusses future developments and challenges, anticipating the transformative role of activatable AIE therapeutics in enhancing tumor therapy.
ISSN:2692-4560
2692-4560
DOI:10.1002/agt2.503